This study has the following several limitations: (i) We only used two sorafenib-resistant HCC cell lines; (ii) expanded clinical studies are needed, including in sorafenib-resistant HCC patients with HBV infection, sorafenib-resistant HCC patients with high or low FGFR4 expression, and an investigation of a promising strategy, such as combination therapy with lenvatinib. The gene discussed is FGFR4; the disease is hepatocellular carcinoma.